HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan

31
17
Favorite

HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan

Reuters2021-06-10

** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains

** Stock on track for the best day since May 31

** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)

** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close

** Co says it does not expect the placing to have any adverse effect on its operations

** Morgan Stanley & Co International PLC is the placing agent

** Hong Kong's healthcare index climbs 0.6%

** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%

** As of last close, the stock had risen 8.3% this year

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（17）

doraaaa
·2021-06-10
Ok
Reply
1
Report
Melanie85
·2021-06-10
Comment pls.
Reply
2
Report
Fold Replies
- ckww:
  Ok
  2021-06-10
  Reply
  Report
ppangsy
·2021-06-10
Amazing! Are you all vested too?
Reply
Like
Report
BBBBBBBBBB
·2021-06-10
Like n comment pls
Reply
4
Report
Fold Replies
- PanaCota:
  syiok
  2021-06-11
  Reply
  Report
- doraaaa:
  ok
  2021-06-10
  Reply
  Report
- Ly99:
  Ok
  2021-06-10
  Reply
  Report
View more 1 comments
Xiao8
·2021-06-10
[Smile]
Reply
1
Report
Fold Replies
- WannWah:
  Like and share
  2021-06-10
  Reply
  Report
Desmond669
·2021-06-10
Good
Reply
1
Report
Kendra96
·2021-06-10
like and comment pls
Reply
2
Report
Fold Replies
- Desmond669:
  Ok
  2021-06-10
  Reply
  Report
- Stonksboi:
  Reply back thanks
  2021-06-10
  Reply
  Report
peggy85
·2021-06-10
so good
Reply
2
Report
Fold Replies
- NiuNiuNiu:
  Good good
  2021-06-10
  Reply
  Report
TopGainerz
·2021-06-10
Ok
Reply
Like
Report
Jw_Jw
·2021-06-10
不錯不錯還可以
Reply
2
Report
sfleong1
·2021-06-10
Oh
Reply
3
Report
PankajRuth
·2021-06-10
???
Reply
3
Report
PankajRuth
·2021-06-10
Comment
Reply
5
Report
Fold Replies
- Stonksboi:
  Reply thanks
  2021-06-10
  Reply
  Report
- Kendra96:
  Done
  2021-06-10
  Reply
  Report
- Stonksboi:
  Reply back thanks
  2021-06-10
  Reply
  Report
View more 2 comments
ConanToh
·2021-06-10
please help to comment and like thanks
Reply
3
Report
Fold Replies
- Stonksboi:
  Reply thanks
  2021-06-10
  Reply
  Report
- Yiqiderrick:
  Nice. Comment n like pls
  2021-06-10
  Reply
  Report
- Stonksboi:
  Reply back thanks
  2021-06-10
  Reply
  Report
View more 2 comments
ConanToh
·2021-06-10
please comment and like for me thanks
Reply
2
Report
Fold Replies
- WayneSing:
  comment back thanks
  2021-06-10
  Reply
  Report
Kikiki
·2021-06-10
M no o
Reply
5
Report
Fold Replies
- Kikiki:
  Bjo
  2021-06-16
  Reply
  Report
- Kikiki:
  Hhj
  2021-06-16
  Reply
  Report
- Kikiki:
  Cg
  2021-06-14
  Reply
  Report
View more 2 comments
BOTAKYAP
·2021-06-10
Comment and like please
Reply
3
Report
Fold Replies
- Stonksboi:
  Reply thanks
  2021-06-10
  Reply
  Report
- Stonksboi:
  Reply back thanks
  2021-06-10
  Reply
  Report
- ConanToh:
  done please help me
  2021-06-10
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2142241372?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-10 12:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2142241372","market":"hk","top_or_hot":-1,"title":"HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan","media":"Reuters","content":"<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Ocumension Therapeutics hits near 5-month high on share sale plan\n</h2>\n\n<h4 class=\"meta\">\n\n2021-06-10 12:58 北京时间&nbsp;&nbsp;&nbsp;<strong>Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01477","symbol_name":"欧康维视生物-B","start_time":0,"source_url":null,"article_id":"2142241372","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2142241372","pubTimestamp":1623301086,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01477":"欧康维视生物-B"},"translate_title":"香港上市公司Ocumension Therapeutics出售股票计划触及近5个月高点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":0.9},"content_text":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)\n** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close\n** Co says it does not expect the placing to have any adverse effect on its operations\n** Morgan Stanley & Co International PLC is the placing agent\n** Hong Kong's healthcare index climbs 0.6%\n** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%\n** As of last close, the stock had risen 8.3% this year","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":183333675,"gmtCreate":1623305938297,"gmtModify":1704200522651,"author":{"id":"3581395444646103","authorId":"3581395444646103","name":"doraaaa","avatar":"https://community-static.tradeup.com/news/89f4634f3adccf2204fadaac66e2947d","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581395444646103","authorIdStr":"3581395444646103"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183333675","repostId":2142241372,"repostType":4,"repost":{"id":"2142241372","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623301086,"share":"https://ttm.financial/m/news/2142241372?lang=&edition=fundamental","pubTime":"2021-06-10 12:58","market":"hk","language":"en","title":"HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2142241372","media":"Reuters","summary":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, ","content":"<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Ocumension Therapeutics hits near 5-month high on share sale plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-10 12:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01477":"欧康维视生物-B"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142241372","content_text":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)\n** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close\n** Co says it does not expect the placing to have any adverse effect on its operations\n** Morgan Stanley & Co International PLC is the placing agent\n** Hong Kong's healthcare index climbs 0.6%\n** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%\n** As of last close, the stock had risen 8.3% this year","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":183978533,"gmtCreate":1623304115222,"gmtModify":1704200484402,"author":{"id":"3568551007910230","authorId":"3568551007910230","name":"Melanie85","avatar":"https://static.tigerbbs.com/12da6320c0aa0175de96553f90b90457","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3568551007910230","authorIdStr":"3568551007910230"},"htmlText":"Comment pls.&nbsp;","listText":"Comment pls.&nbsp;","text":"Comment pls.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/183978533","repostId":2142241372,"repostType":4,"repost":{"id":"2142241372","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623301086,"share":"https://ttm.financial/m/news/2142241372?lang=&edition=fundamental","pubTime":"2021-06-10 12:58","market":"hk","language":"en","title":"HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2142241372","media":"Reuters","summary":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, ","content":"<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Ocumension Therapeutics hits near 5-month high on share sale plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-10 12:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01477":"欧康维视生物-B"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142241372","content_text":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)\n** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close\n** Co says it does not expect the placing to have any adverse effect on its operations\n** Morgan Stanley & Co International PLC is the placing agent\n** Hong Kong's healthcare index climbs 0.6%\n** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%\n** As of last close, the stock had risen 8.3% this year","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4662947,"gmtCreate":1623304945320,"gmtModify":1663228347936,"authorId":3581586523786578,"author":{"id":3581586523786578,"idStr":"3581586523786578","authorId":3581586523786578,"name":"ckww","avatar":"https://static.tigerbbs.com/bc2cc1ef6533d547201ce880e7c04b9c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183978533,"type":1,"supId":0,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"}],"langContent":"EN"},{"id":183946915,"gmtCreate":1623303412437,"gmtModify":1704200470216,"author":{"id":"3585096019201823","authorId":"3585096019201823","name":"ppangsy","avatar":"https://static.tigerbbs.com/20471738d34ed6efdb59281b8fc3b6c8","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3585096019201823","authorIdStr":"3585096019201823"},"htmlText":"Amazing! Are you all vested too?","listText":"Amazing! Are you all vested too?","text":"Amazing! Are you all vested too?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183946915","repostId":2142241372,"repostType":4,"repost":{"id":"2142241372","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623301086,"share":"https://ttm.financial/m/news/2142241372?lang=&edition=fundamental","pubTime":"2021-06-10 12:58","market":"hk","language":"en","title":"HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2142241372","media":"Reuters","summary":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, ","content":"<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Ocumension Therapeutics hits near 5-month high on share sale plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-10 12:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01477":"欧康维视生物-B"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142241372","content_text":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)\n** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close\n** Co says it does not expect the placing to have any adverse effect on its operations\n** Morgan Stanley & Co International PLC is the placing agent\n** Hong Kong's healthcare index climbs 0.6%\n** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%\n** As of last close, the stock had risen 8.3% this year","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":183943102,"gmtCreate":1623303184306,"gmtModify":1704200465836,"author":{"id":"3581562365927542","authorId":"3581562365927542","name":"BBBBBBBBBB","avatar":"https://static.tigerbbs.com/973395458d7e1db24dbd4a689c79e8a2","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581562365927542","authorIdStr":"3581562365927542"},"htmlText":"Like n comment pls&nbsp;","listText":"Like n comment pls&nbsp;","text":"Like n comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/183943102","repostId":2142241372,"repostType":4,"repost":{"id":"2142241372","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623301086,"share":"https://ttm.financial/m/news/2142241372?lang=&edition=fundamental","pubTime":"2021-06-10 12:58","market":"hk","language":"en","title":"HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2142241372","media":"Reuters","summary":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, ","content":"<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Ocumension Therapeutics hits near 5-month high on share sale plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-10 12:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01477":"欧康维视生物-B"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142241372","content_text":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)\n** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close\n** Co says it does not expect the placing to have any adverse effect on its operations\n** Morgan Stanley & Co International PLC is the placing agent\n** Hong Kong's healthcare index climbs 0.6%\n** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%\n** As of last close, the stock had risen 8.3% this year","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4677243,"gmtCreate":1623377042421,"gmtModify":1663228420647,"authorId":3581588474178431,"author":{"id":3581588474178431,"idStr":"3581588474178431","authorId":3581588474178431,"name":"PanaCota","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183943102,"type":1,"supId":0,"prevId":0,"content":"syiok","text":"syiok","html":"syiok"},{"id":4663104,"gmtCreate":1623305946805,"gmtModify":1663228350549,"authorId":3581395444646103,"author":{"id":3581395444646103,"idStr":"3581395444646103","authorId":3581395444646103,"name":"doraaaa","avatar":"https://community-static.tradeup.com/news/89f4634f3adccf2204fadaac66e2947d","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183943102,"type":1,"supId":4663030,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":4663030,"gmtCreate":1623305583518,"gmtModify":1663228350342,"authorId":3582633189757328,"author":{"id":3582633189757328,"idStr":"3582633189757328","authorId":3582633189757328,"name":"Ly99","avatar":"https://static.tigerbbs.com/ad04aa6a4345f682b5fa75c514b9b871","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183943102,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":4662732,"gmtCreate":1623303821432,"gmtModify":1663228347942,"authorId":3575777532787835,"author":{"id":3575777532787835,"idStr":"3575777532787835","authorId":3575777532787835,"name":"4ebeaef4","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183943102,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":183956515,"gmtCreate":1623302726237,"gmtModify":1704200455858,"author":{"id":"3582746115408690","authorId":"3582746115408690","name":"Xiao8","avatar":"https://static.tigerbbs.com/22d090e5d2108456962627f7ef25270b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582746115408690","authorIdStr":"3582746115408690"},"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/183956515","repostId":2142241372,"repostType":4,"repost":{"id":"2142241372","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623301086,"share":"https://ttm.financial/m/news/2142241372?lang=&edition=fundamental","pubTime":"2021-06-10 12:58","market":"hk","language":"en","title":"HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2142241372","media":"Reuters","summary":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, ","content":"<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Ocumension Therapeutics hits near 5-month high on share sale plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-10 12:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01477":"欧康维视生物-B"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142241372","content_text":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)\n** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close\n** Co says it does not expect the placing to have any adverse effect on its operations\n** Morgan Stanley & Co International PLC is the placing agent\n** Hong Kong's healthcare index climbs 0.6%\n** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%\n** As of last close, the stock had risen 8.3% this year","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4662578,"gmtCreate":1623302927859,"gmtModify":1663228346157,"authorId":3581902399516412,"author":{"id":3581902399516412,"idStr":"3581902399516412","authorId":3581902399516412,"name":"WannWah","avatar":"https://static.tigerbbs.com/f999607e2749596598ba5a5db56740c2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183956515,"type":1,"supId":0,"prevId":0,"content":"Like and share","text":"Like and share","html":"Like and share"}],"langContent":"EN"},{"id":183951871,"gmtCreate":1623302473793,"gmtModify":1704200452942,"author":{"id":"3562118563279867","authorId":"3562118563279867","name":"Desmond669","avatar":"https://static.tigerbbs.com/e2484115c94d3471cb46f20ea7598b4a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3562118563279867","authorIdStr":"3562118563279867"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183951871","repostId":2142241372,"repostType":4,"repost":{"id":"2142241372","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623301086,"share":"https://ttm.financial/m/news/2142241372?lang=&edition=fundamental","pubTime":"2021-06-10 12:58","market":"hk","language":"en","title":"HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2142241372","media":"Reuters","summary":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, ","content":"<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Ocumension Therapeutics hits near 5-month high on share sale plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-10 12:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01477":"欧康维视生物-B"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142241372","content_text":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)\n** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close\n** Co says it does not expect the placing to have any adverse effect on its operations\n** Morgan Stanley & Co International PLC is the placing agent\n** Hong Kong's healthcare index climbs 0.6%\n** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%\n** As of last close, the stock had risen 8.3% this year","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":183953707,"gmtCreate":1623302424609,"gmtModify":1704200452133,"author":{"id":"3582771898046048","authorId":"3582771898046048","name":"Kendra96","avatar":"https://static.tigerbbs.com/96ff91316ee8de797a1d13b29518fa98","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582771898046048","authorIdStr":"3582771898046048"},"htmlText":"like and comment pls","listText":"like and comment pls","text":"like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/183953707","repostId":2142241372,"repostType":4,"repost":{"id":"2142241372","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623301086,"share":"https://ttm.financial/m/news/2142241372?lang=&edition=fundamental","pubTime":"2021-06-10 12:58","market":"hk","language":"en","title":"HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2142241372","media":"Reuters","summary":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, ","content":"<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Ocumension Therapeutics hits near 5-month high on share sale plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-10 12:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01477":"欧康维视生物-B"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142241372","content_text":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)\n** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close\n** Co says it does not expect the placing to have any adverse effect on its operations\n** Morgan Stanley & Co International PLC is the placing agent\n** Hong Kong's healthcare index climbs 0.6%\n** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%\n** As of last close, the stock had risen 8.3% this year","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4662504,"gmtCreate":1623302483456,"gmtModify":1663228347049,"authorId":3562118563279867,"author":{"id":3562118563279867,"idStr":"3562118563279867","authorId":3562118563279867,"name":"Desmond669","avatar":"https://static.tigerbbs.com/e2484115c94d3471cb46f20ea7598b4a","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.05.31","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183953707,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":4662526,"gmtCreate":1623302637877,"gmtModify":1663228344947,"authorId":3582084463458542,"author":{"id":3582084463458542,"idStr":"3582084463458542","authorId":3582084463458542,"name":"Stonksboi","avatar":"https://static.tigerbbs.com/438d081eba3c41d4725ec304bd3ba10f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183953707,"type":1,"supId":0,"prevId":0,"content":"Reply back thanks","text":"Reply back thanks","html":"Reply back thanks"}],"langContent":"EN"},{"id":183953804,"gmtCreate":1623302349808,"gmtModify":1704200451328,"author":{"id":"3581811291499435","authorId":"3581811291499435","name":"peggy85","avatar":"https://static.tigerbbs.com/e664ba5e10199decb88d9dc807352693","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581811291499435","authorIdStr":"3581811291499435"},"htmlText":"so good","listText":"so good","text":"so good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/183953804","repostId":2142241372,"repostType":4,"repost":{"id":"2142241372","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623301086,"share":"https://ttm.financial/m/news/2142241372?lang=&edition=fundamental","pubTime":"2021-06-10 12:58","market":"hk","language":"en","title":"HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2142241372","media":"Reuters","summary":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, ","content":"<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Ocumension Therapeutics hits near 5-month high on share sale plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-10 12:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01477":"欧康维视生物-B"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142241372","content_text":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)\n** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close\n** Co says it does not expect the placing to have any adverse effect on its operations\n** Morgan Stanley & Co International PLC is the placing agent\n** Hong Kong's healthcare index climbs 0.6%\n** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%\n** As of last close, the stock had risen 8.3% this year","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4662552,"gmtCreate":1623302748389,"gmtModify":1663228345938,"authorId":3574498683107413,"author":{"id":3574498683107413,"idStr":"3574498683107413","authorId":3574498683107413,"name":"NiuNiuNiu","avatar":"https://static.tigerbbs.com/afecf7552dea242143cc6313f9b425ee","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183953804,"type":1,"supId":0,"prevId":0,"content":"Good good ","text":"Good good ","html":"Good good "}],"langContent":"EN"},{"id":183950509,"gmtCreate":1623302112401,"gmtModify":1704200449377,"author":{"id":"3575522252515458","authorId":"3575522252515458","name":"TopGainerz","avatar":"https://static.tigerbbs.com/921c1dab7d7dca9ee43859f8ffc4aefc","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3575522252515458","authorIdStr":"3575522252515458"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183950509","repostId":2142241372,"repostType":4,"repost":{"id":"2142241372","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623301086,"share":"https://ttm.financial/m/news/2142241372?lang=&edition=fundamental","pubTime":"2021-06-10 12:58","market":"hk","language":"en","title":"HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2142241372","media":"Reuters","summary":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, ","content":"<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Ocumension Therapeutics hits near 5-month high on share sale plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-10 12:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01477":"欧康维视生物-B"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142241372","content_text":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)\n** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close\n** Co says it does not expect the placing to have any adverse effect on its operations\n** Morgan Stanley & Co International PLC is the placing agent\n** Hong Kong's healthcare index climbs 0.6%\n** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%\n** As of last close, the stock had risen 8.3% this year","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":183926711,"gmtCreate":1623301787233,"gmtModify":1704200441409,"author":{"id":"3551593670769209","authorId":"3551593670769209","name":"Jw_Jw","avatar":"https://static.tigerbbs.com/1eb2f56ab15cffc6fe132255cb9206bd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3551593670769209","authorIdStr":"3551593670769209"},"htmlText":"不 錯不錯 還可以","listText":"不 錯不錯 還可以","text":"不 錯不錯 還可以","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183926711","repostId":2142241372,"repostType":4,"repost":{"id":"2142241372","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623301086,"share":"https://ttm.financial/m/news/2142241372?lang=&edition=fundamental","pubTime":"2021-06-10 12:58","market":"hk","language":"en","title":"HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2142241372","media":"Reuters","summary":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, ","content":"<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Ocumension Therapeutics hits near 5-month high on share sale plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-10 12:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01477":"欧康维视生物-B"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142241372","content_text":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)\n** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close\n** Co says it does not expect the placing to have any adverse effect on its operations\n** Morgan Stanley & Co International PLC is the placing agent\n** Hong Kong's healthcare index climbs 0.6%\n** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%\n** As of last close, the stock had risen 8.3% this year","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":183928571,"gmtCreate":1623301712593,"gmtModify":1704200439466,"author":{"id":"3583570345500843","authorId":"3583570345500843","name":"sfleong1","avatar":"https://static.tigerbbs.com/2ec42f3f2b911279950a45a9140bc358","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583570345500843","authorIdStr":"3583570345500843"},"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183928571","repostId":2142241372,"repostType":4,"repost":{"id":"2142241372","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623301086,"share":"https://ttm.financial/m/news/2142241372?lang=&edition=fundamental","pubTime":"2021-06-10 12:58","market":"hk","language":"en","title":"HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2142241372","media":"Reuters","summary":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, ","content":"<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Ocumension Therapeutics hits near 5-month high on share sale plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-10 12:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01477":"欧康维视生物-B"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142241372","content_text":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)\n** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close\n** Co says it does not expect the placing to have any adverse effect on its operations\n** Morgan Stanley & Co International PLC is the placing agent\n** Hong Kong's healthcare index climbs 0.6%\n** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%\n** As of last close, the stock had risen 8.3% this year","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":183928331,"gmtCreate":1623301681923,"gmtModify":1704200439142,"author":{"id":"3585895733058794","authorId":"3585895733058794","name":"PankajRuth","avatar":"https://community-static.tradeup.com/news/09d8da5cc4cfad4a4a8b60f6aaca1f48","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3585895733058794","authorIdStr":"3585895733058794"},"htmlText":"???","listText":"???","text":"???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183928331","repostId":2142241372,"repostType":4,"repost":{"id":"2142241372","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623301086,"share":"https://ttm.financial/m/news/2142241372?lang=&edition=fundamental","pubTime":"2021-06-10 12:58","market":"hk","language":"en","title":"HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2142241372","media":"Reuters","summary":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, ","content":"<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Ocumension Therapeutics hits near 5-month high on share sale plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-10 12:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01477":"欧康维视生物-B"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142241372","content_text":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)\n** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close\n** Co says it does not expect the placing to have any adverse effect on its operations\n** Morgan Stanley & Co International PLC is the placing agent\n** Hong Kong's healthcare index climbs 0.6%\n** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%\n** As of last close, the stock had risen 8.3% this year","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":183921905,"gmtCreate":1623301630607,"gmtModify":1704200437843,"author":{"id":"3585895733058794","authorId":"3585895733058794","name":"PankajRuth","avatar":"https://community-static.tradeup.com/news/09d8da5cc4cfad4a4a8b60f6aaca1f48","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3585895733058794","authorIdStr":"3585895733058794"},"htmlText":"Comment&nbsp;","listText":"Comment&nbsp;","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/183921905","repostId":2142241372,"repostType":4,"repost":{"id":"2142241372","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623301086,"share":"https://ttm.financial/m/news/2142241372?lang=&edition=fundamental","pubTime":"2021-06-10 12:58","market":"hk","language":"en","title":"HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2142241372","media":"Reuters","summary":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, ","content":"<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Ocumension Therapeutics hits near 5-month high on share sale plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-10 12:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01477":"欧康维视生物-B"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142241372","content_text":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)\n** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close\n** Co says it does not expect the placing to have any adverse effect on its operations\n** Morgan Stanley & Co International PLC is the placing agent\n** Hong Kong's healthcare index climbs 0.6%\n** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%\n** As of last close, the stock had risen 8.3% this year","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4662541,"gmtCreate":1623302699373,"gmtModify":1663228349144,"authorId":3582084463458542,"author":{"id":3582084463458542,"idStr":"3582084463458542","authorId":3582084463458542,"name":"Stonksboi","avatar":"https://static.tigerbbs.com/438d081eba3c41d4725ec304bd3ba10f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183921905,"type":1,"supId":4662410,"prevId":0,"content":"Reply thanks","text":"Reply thanks","html":"Reply thanks"},{"id":4662493,"gmtCreate":1623302439740,"gmtModify":1663228347945,"authorId":3582771898046048,"author":{"id":3582771898046048,"idStr":"3582771898046048","authorId":3582771898046048,"name":"Kendra96","avatar":"https://static.tigerbbs.com/96ff91316ee8de797a1d13b29518fa98","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183921905,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":4662529,"gmtCreate":1623302645761,"gmtModify":1663228347735,"authorId":3582084463458542,"author":{"id":3582084463458542,"idStr":"3582084463458542","authorId":3582084463458542,"name":"Stonksboi","avatar":"https://static.tigerbbs.com/438d081eba3c41d4725ec304bd3ba10f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183921905,"type":1,"supId":0,"prevId":0,"content":"Reply back thanks","text":"Reply back thanks","html":"Reply back thanks"},{"id":4662781,"gmtCreate":1623304080862,"gmtModify":1663228345936,"authorId":3577525278195004,"author":{"id":3577525278195004,"idStr":"3577525278195004","authorId":3577525278195004,"name":"DLiew","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3582084463458542,"repliedAuthor":{"id":3582084463458542,"idStr":"3582084463458542","authorId":3582084463458542,"name":"Stonksboi","avatar":"https://static.tigerbbs.com/438d081eba3c41d4725ec304bd3ba10f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":183921905,"type":1,"supId":4662410,"prevId":4662541,"content":"<u>Thanks</u>","text":"<u>Thanks</u>","html":"<u>Thanks</u>"},{"id":4662410,"gmtCreate":1623301878041,"gmtModify":1663228345845,"authorId":3577525278195004,"author":{"id":3577525278195004,"idStr":"3577525278195004","authorId":3577525278195004,"name":"DLiew","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183921905,"type":1,"supId":0,"prevId":0,"content":"Respond to comment <u>pls</u>","text":"Respond to comment <u>pls</u>","html":"Respond to comment <u>pls</u>"}],"langContent":"EN"},{"id":183923123,"gmtCreate":1623301568262,"gmtModify":1704200436706,"author":{"id":"3578621924333526","authorId":"3578621924333526","name":"ConanToh","avatar":"https://static.tigerbbs.com/17bf1e09858b72f85e5e8efda2fbed84","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578621924333526","authorIdStr":"3578621924333526"},"htmlText":"please help to comment and like thanks","listText":"please help to comment and like thanks","text":"please help to comment and like thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/183923123","repostId":2142241372,"repostType":4,"repost":{"id":"2142241372","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623301086,"share":"https://ttm.financial/m/news/2142241372?lang=&edition=fundamental","pubTime":"2021-06-10 12:58","market":"hk","language":"en","title":"HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2142241372","media":"Reuters","summary":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, ","content":"<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Ocumension Therapeutics hits near 5-month high on share sale plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-10 12:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01477":"欧康维视生物-B"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142241372","content_text":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)\n** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close\n** Co says it does not expect the placing to have any adverse effect on its operations\n** Morgan Stanley & Co International PLC is the placing agent\n** Hong Kong's healthcare index climbs 0.6%\n** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%\n** As of last close, the stock had risen 8.3% this year","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4662536,"gmtCreate":1623302687555,"gmtModify":1663228346645,"authorId":3582084463458542,"author":{"id":3582084463458542,"idStr":"3582084463458542","authorId":3582084463458542,"name":"Stonksboi","avatar":"https://static.tigerbbs.com/438d081eba3c41d4725ec304bd3ba10f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183923123,"type":1,"supId":4662371,"prevId":0,"content":"Reply thanks","text":"Reply thanks","html":"Reply thanks"},{"id":4662371,"gmtCreate":1623301628709,"gmtModify":1663228346633,"authorId":3570010617930347,"author":{"id":3570010617930347,"idStr":"3570010617930347","authorId":3570010617930347,"name":"Yiqiderrick","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183923123,"type":1,"supId":0,"prevId":0,"content":"Nice. Comment n like pls ","text":"Nice. Comment n like pls ","html":"Nice. Comment n like pls "},{"id":4662530,"gmtCreate":1623302655780,"gmtModify":1663228346039,"authorId":3582084463458542,"author":{"id":3582084463458542,"idStr":"3582084463458542","authorId":3582084463458542,"name":"Stonksboi","avatar":"https://static.tigerbbs.com/438d081eba3c41d4725ec304bd3ba10f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183923123,"type":1,"supId":0,"prevId":0,"content":"Reply back thanks","text":"Reply back thanks","html":"Reply back thanks"},{"id":4662567,"gmtCreate":1623302821237,"gmtModify":1663228345750,"authorId":3584427442291849,"author":{"id":3584427442291849,"idStr":"3584427442291849","authorId":3584427442291849,"name":"WayneSing","avatar":"https://static.tigerbbs.com/9ba5be2ddf8347d41eed59a863adfe57","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183923123,"type":1,"supId":0,"prevId":0,"content":"comment back thanks","text":"comment back thanks","html":"comment back thanks"},{"id":4662372,"gmtCreate":1623301633136,"gmtModify":1663228344444,"authorId":3578621924333526,"author":{"id":3578621924333526,"idStr":"3578621924333526","authorId":3578621924333526,"name":"ConanToh","avatar":"https://static.tigerbbs.com/17bf1e09858b72f85e5e8efda2fbed84","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.08","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183923123,"type":1,"supId":0,"prevId":0,"content":"done","text":"done","html":"done"}],"langContent":"EN"},{"id":183920750,"gmtCreate":1623301495170,"gmtModify":1704200434435,"author":{"id":"3578621924333526","authorId":"3578621924333526","name":"ConanToh","avatar":"https://static.tigerbbs.com/17bf1e09858b72f85e5e8efda2fbed84","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578621924333526","authorIdStr":"3578621924333526"},"htmlText":"please comment and like for me thanks","listText":"please comment and like for me thanks","text":"please comment and like for me thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/183920750","repostId":2142241372,"repostType":4,"repost":{"id":"2142241372","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623301086,"share":"https://ttm.financial/m/news/2142241372?lang=&edition=fundamental","pubTime":"2021-06-10 12:58","market":"hk","language":"en","title":"HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2142241372","media":"Reuters","summary":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, ","content":"<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Ocumension Therapeutics hits near 5-month high on share sale plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-10 12:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01477":"欧康维视生物-B"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142241372","content_text":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)\n** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close\n** Co says it does not expect the placing to have any adverse effect on its operations\n** Morgan Stanley & Co International PLC is the placing agent\n** Hong Kong's healthcare index climbs 0.6%\n** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%\n** As of last close, the stock had risen 8.3% this year","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4662564,"gmtCreate":1623302807786,"gmtModify":1663228349335,"authorId":3584427442291849,"author":{"id":3584427442291849,"idStr":"3584427442291849","authorId":3584427442291849,"name":"WayneSing","avatar":"https://static.tigerbbs.com/9ba5be2ddf8347d41eed59a863adfe57","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183920750,"type":1,"supId":0,"prevId":0,"content":"comment back thanks","text":"comment back thanks","html":"comment back thanks"}],"langContent":"EN"},{"id":183920854,"gmtCreate":1623301476578,"gmtModify":1704200433789,"author":{"id":"3581229547024496","authorId":"3581229547024496","name":"Kikiki","avatar":"https://static.tigerbbs.com/f46fbae3962077a32ec82d426edd72ad","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":2,"crmLevelSwitch":0,"idStr":"3581229547024496","authorIdStr":"3581229547024496"},"htmlText":"&nbsp;M no o","listText":"&nbsp;M no o","text":"M no o","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":9,"repostSize":0,"link":"https://ttm.financial/post/183920854","repostId":2142241372,"repostType":4,"repost":{"id":"2142241372","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623301086,"share":"https://ttm.financial/m/news/2142241372?lang=&edition=fundamental","pubTime":"2021-06-10 12:58","market":"hk","language":"en","title":"HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2142241372","media":"Reuters","summary":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, ","content":"<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Ocumension Therapeutics hits near 5-month high on share sale plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-10 12:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01477":"欧康维视生物-B"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142241372","content_text":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)\n** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close\n** Co says it does not expect the placing to have any adverse effect on its operations\n** Morgan Stanley & Co International PLC is the placing agent\n** Hong Kong's healthcare index climbs 0.6%\n** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%\n** As of last close, the stock had risen 8.3% this year","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4803419,"gmtCreate":1623822097212,"gmtModify":1663228995531,"authorId":3581229547024496,"author":{"id":3581229547024496,"idStr":"3581229547024496","authorId":3581229547024496,"name":"Kikiki","avatar":"https://static.tigerbbs.com/f46fbae3962077a32ec82d426edd72ad","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"80.65%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183920854,"type":1,"supId":0,"prevId":0,"content":"Bjo","text":"Bjo","html":"Bjo"},{"id":4787833,"gmtCreate":1623777397793,"gmtModify":1663228927235,"authorId":3581229547024496,"author":{"id":3581229547024496,"idStr":"3581229547024496","authorId":3581229547024496,"name":"Kikiki","avatar":"https://static.tigerbbs.com/f46fbae3962077a32ec82d426edd72ad","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"80.65%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183920854,"type":1,"supId":0,"prevId":0,"content":"  Hhj","text":"  Hhj","html":"  Hhj"},{"id":4746095,"gmtCreate":1623663312081,"gmtModify":1663228737244,"authorId":3581229547024496,"author":{"id":3581229547024496,"idStr":"3581229547024496","authorId":3581229547024496,"name":"Kikiki","avatar":"https://static.tigerbbs.com/f46fbae3962077a32ec82d426edd72ad","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"80.65%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183920854,"type":1,"supId":0,"prevId":0,"content":" Cg","text":" Cg","html":" Cg"},{"id":4678023,"gmtCreate":1623379714290,"gmtModify":1663228423732,"authorId":3581229547024496,"author":{"id":3581229547024496,"idStr":"3581229547024496","authorId":3581229547024496,"name":"Kikiki","avatar":"https://static.tigerbbs.com/f46fbae3962077a32ec82d426edd72ad","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"80.65%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183920854,"type":1,"supId":4662566,"prevId":0,"content":"v","text":"v","html":"v"},{"id":4662978,"gmtCreate":1623305222857,"gmtModify":1663228351954,"authorId":3581229547024496,"author":{"id":3581229547024496,"idStr":"3581229547024496","authorId":3581229547024496,"name":"Kikiki","avatar":"https://static.tigerbbs.com/f46fbae3962077a32ec82d426edd72ad","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"80.65%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183920854,"type":1,"supId":4662566,"prevId":0,"content":"D","text":"D","html":"D"}],"langContent":"EN"},{"id":183967540,"gmtCreate":1623301401980,"gmtModify":1704200433627,"author":{"id":"3569894447597850","authorId":"3569894447597850","name":"BOTAKYAP","avatar":"https://static.tigerbbs.com/335356fded8c7d08f8ee1bbe18b6f105","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3569894447597850","authorIdStr":"3569894447597850"},"htmlText":"Comment and like please","listText":"Comment and like please","text":"Comment and like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/183967540","repostId":2142241372,"repostType":4,"repost":{"id":"2142241372","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623301086,"share":"https://ttm.financial/m/news/2142241372?lang=&edition=fundamental","pubTime":"2021-06-10 12:58","market":"hk","language":"en","title":"HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2142241372","media":"Reuters","summary":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, ","content":"<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Ocumension Therapeutics hits near 5-month high on share sale plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Ocumension Therapeutics hits near 5-month high on share sale plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-10 12:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains</p>\n<p>** Stock on track for the best day since May 31</p>\n<p>** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)</p>\n<p>** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou <a href=\"https://laohu8.com/S/FRO\">Frontline</a> BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close</p>\n<p>** Co says it does not expect the placing to have any adverse effect on its operations</p>\n<p>** <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co International <a href=\"https://laohu8.com/S/PLC\">PLC</a> is the placing agent</p>\n<p>** Hong Kong's healthcare index climbs 0.6%</p>\n<p>** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%</p>\n<p>** As of last close, the stock had risen 8.3% this year</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01477":"欧康维视生物-B"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142241372","content_text":"** Shares of Ocumension Therapeutics rise as much as 9.6% to HK$32.05, their highest since Jan. 18, and on course for second session of gains\n** Stock on track for the best day since May 31\n** China-based ophthalmic therapies developer says major shareholders plan sale of 1.36% of the company stake to third-party investors for HK$236.5 mln ($30.5 mln)\n** The major shareholders, including 6 Dimensions Capital, 6 Dimensions Affiliates Fund, Suzhou Frontline BioVentures Venture Capital Fund II, and Suzhou 6Dimensions Venture Capital Partnership, plan sale of 8.6 mln existing shares at HK$27.50 each, or 6% discount to Wednesday's close\n** Co says it does not expect the placing to have any adverse effect on its operations\n** Morgan Stanley & Co International PLC is the placing agent\n** Hong Kong's healthcare index climbs 0.6%\n** Both the Hang Seng China enterprises index and the benchmark index gain 0.3%\n** As of last close, the stock had risen 8.3% this year","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4662535,"gmtCreate":1623302673588,"gmtModify":1663228347828,"authorId":3582084463458542,"author":{"id":3582084463458542,"idStr":"3582084463458542","authorId":3582084463458542,"name":"Stonksboi","avatar":"https://static.tigerbbs.com/438d081eba3c41d4725ec304bd3ba10f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183967540,"type":1,"supId":4662349,"prevId":0,"content":"Reply thanks","text":"Reply thanks","html":"Reply thanks"},{"id":4662532,"gmtCreate":1623302662560,"gmtModify":1663228346936,"authorId":3582084463458542,"author":{"id":3582084463458542,"idStr":"3582084463458542","authorId":3582084463458542,"name":"Stonksboi","avatar":"https://static.tigerbbs.com/438d081eba3c41d4725ec304bd3ba10f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183967540,"type":1,"supId":0,"prevId":0,"content":"Reply back thanks","text":"Reply back thanks","html":"Reply back thanks"},{"id":4662349,"gmtCreate":1623301484480,"gmtModify":1663228344741,"authorId":3578621924333526,"author":{"id":3578621924333526,"idStr":"3578621924333526","authorId":3578621924333526,"name":"ConanToh","avatar":"https://static.tigerbbs.com/17bf1e09858b72f85e5e8efda2fbed84","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.08","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183967540,"type":1,"supId":0,"prevId":0,"content":"done please help me","text":"done please help me","html":"done please help me"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":31,"commentSize":17,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}